O'Grady Thomas J, Rinaldi Sabina, Michels Kara A, Adami Hans-Olov, Buring Julie E, Chen Yu, Clendenen Tess V, D'Aloisio Aimee, DeHart Jessica Clague, Franceschi Silvia, Freedman Neal D, Gierach Gretchen L, Giles Graham G, Lacey James V, Lee I-Min, Liao Linda M, Linet Martha S, McCullough Marjorie L, Patel Alpa V, Prizment Anna, Robien Kim, Sandler Dale P, Stolzenberg-Solomon Rachael, Weiderpass Elisabete, White Emily, Wolk Alicja, Zheng Wei, Berrington de Gonzalez Amy, Kitahara Cari M
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Department of Epidemiology and Biostatistics, University at Albany School of Public Health, Albany, NY, USA.
Int J Epidemiol. 2024 Feb 1;53(1). doi: 10.1093/ije/dyad172.
The incidence of differentiated thyroid cancer (DTC) is higher in women than in men but whether sex steroid hormones contribute to this difference remains unclear. Studies of reproductive and hormonal factors and thyroid cancer risk have provided inconsistent results.
Original data from 1 252 907 women in 16 cohorts in North America, Europe, Australia and Asia were combined to evaluate associations of DTC risk with reproductive and hormonal factors. Multivariable-adjusted Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95% CIs.
During follow-up, 2142 women were diagnosed with DTC. Factors associated with higher risk of DTC included younger age at menarche (<10 vs 10-11 years; HR, 1.28; 95% CI, 1.00-1.64), younger (<40; HR, 1.31; 95% CI, 1.05-1.62) and older (≥55; HR, 1.33; 95% CI, 1.05-1.68) ages at menopause (vs 40-44 years), ever use of menopausal hormone therapy (HR, 1.16; 95% CI, 1.02-1.33) and previous hysterectomy (HR, 1.25; 95% CI, 1.13-1.39) or bilateral oophorectomy (HR, 1.14; 95% CI, 1.00-1.29). Factors associated with lower risk included longer-term use (≥5 vs <5 years) of oral contraceptives (HR, 0.86; 95% CI, 0.76-0.96) among those who ever used oral contraception and baseline post-menopausal status (HR, 0.82; 95% CI, 0.70-0.96). No associations were observed for parity, duration of menopausal hormone therapy use or lifetime number of reproductive years or ovulatory cycles.
Our study provides some evidence linking reproductive and hormonal factors with risk of DTC. Results should be interpreted cautiously considering the modest strength of the associations and potential for exposure misclassification and detection bias. Prospective studies of pre-diagnostic circulating sex steroid hormone measurements and DTC risk may provide additional insight.
分化型甲状腺癌(DTC)的发病率女性高于男性,但性类固醇激素是否导致了这种差异仍不清楚。关于生殖和激素因素与甲状腺癌风险的研究结果并不一致。
合并了北美、欧洲、澳大利亚和亚洲16个队列中1252907名女性的原始数据,以评估DTC风险与生殖和激素因素之间的关联。使用多变量调整的Cox比例风险模型来估计风险比(HRs)和95%置信区间(CIs)。
在随访期间,2142名女性被诊断为DTC。与DTC风险较高相关的因素包括月经初潮年龄较小(<10岁与10 - 11岁;HR,1.28;95% CI,1.00 - 1.64)、绝经年龄较小(<40岁;HR,1.31;95% CI,1.05 - 1.62)和较大(≥55岁;HR,1.33;95% CI,1.05 - 1.68)(与40 - 44岁相比)、曾经使用过绝经激素治疗(HR,1.16;95% CI,1.02 - 1.33)以及既往子宫切除术(HR,1.25;95% CI,1.13 - 1.39)或双侧卵巢切除术(HR,1.14;95% CI,1.00 - 1.29)。与风险较低相关的因素包括曾经使用口服避孕药的人群中口服避孕药的长期使用(≥5年与<5年)(HR, 0.86;95% CI, 0.76 - 0.96)以及基线绝经后状态(HR, 0.82;95% CI, 0.70 - 0.96)。未观察到与产次、绝经激素治疗使用时长或生殖年限或排卵周期的终生数量之间存在关联。
我们的研究提供了一些将生殖和激素因素与DTC风险联系起来的证据。考虑到关联强度适中以及存在暴露错误分类和检测偏倚的可能性,对结果的解释应谨慎。对诊断前循环性类固醇激素测量与DTC风险的前瞻性研究可能会提供更多见解。